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CHARACTERIZING GLUCOCORTICOID RECEPTOR IN METASTATIC 
CASTRATION RESISTANT PROSTATE CANCER 
MATTHEW ADAM KAHN 
ABSTRACT 
The purpose of this paper is to characterize the glucocorticoid receptor (GR) 
signaling and relevance in the context of enzalutamide resistant prostate cancer cells. 
Enzalutamide is a drug that functions to dampen androgen receptor (AR) signaling, thus 
inhibiting cancer dependency on the receptor protein. Although the application of the 
drug reduces AR signaling in these cancer cells, an alternate pathway involving GR 
signaling may be upregulated as a compensatory bypass mechanism. Therefore, it 
possible that GR assumes the role of AR and facilitates tumor growth by promoting the 
expression of genes regulated by AR. To analyze how GR operates, we analyzed GR 
signaling in enzalutamide resistant metastatic prostate cancer cell lines. We assessed 
protein levels of AR and GR as well as mRNA expression of various AR targets. Our 
results illustrate the expected downregulation of AR and upregulation of GR in 
enzalutamide resistant cells. Furthermore, some canonical AR targets like prostate 
specific antigen (PSA), Prostate Specific Membrane Antigen (PSMA) and Prostatic Acid 
Phosphatase (PAP) were inhibited by a novel GR inhibitor. Thus, this GR inhibitor could 
be used in combination with enzalutamide and create a more potent AR signaling 
blockade. Prostate cancer is a very problematic disease in men and becomes especially 
challenging to treat during the metastatic stage as they are non-sensitive to anti-
androgens. The significance of understanding how GR functions, as well as the potential 
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benefit of blocking GR signaling, may provide insight into novel drugs and agents that 
could specifically target these pathways, control and mitigate cancer growth, and prolong 
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1.1 Overview  
Prostate cancer is one of the leading diseases in men around the world and is the 
second most diagnosed cancer in this group (Bray et al., 2018). Studies outlining the 
comparative incidence rates in United States throughout several years has shown that in 
2004 there was an incidence of 68,814 cases as opposed to 2013 in which there were 
67,070 cases. From 2004 to 2013 there was a total of approximately 767,550 diagnosed 
cases. Given that prostate cancer has different stages of development and thus varying 
levels of risk at the point of diagnosis, stratification of low risk, intermediate risk, high 
risk, and metastatic groups were used to assess incidence rates from years 2004 to 2013. 
There was a significant decrease in incidence of prostate cancer from 2007-2013 in the 
low risk group (30,323 to 16,223). There was a significant increase in incidence of 
prostate cancer from 2004-2008 (27,347 to 40,201) (Mohler et al., 2016). There were no 
significant changes from 2004 to 2013 for the high-risk group, but in terms of the 
metastatic group, there was a significant increase in the incidence from 2007 to 2013 
(1884 to 2890) (Mohler et al., 2016). Significant decreases in incidence rates are most 
probably associated with a decline in the use of PSA testing as a method of early 
diagnosis. Skepticism over the accuracy of the biomarker as an indicator of early cancer 
has led medical professionals to research novel ways for detecting early stage prostate 
cancer (Siegel, Miller, & Jemal, 2019). The estimated number of new prostate cancer 
cases in 2020 in the United States is about 191, 930. The estimated number of deaths 
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associated with prostate cancer for the same year is about 33,330 (Siegel, Miller, & 
Jemal, 2020). 
 Prostate cancer, like many other diseases are associated with various factors that 
may contribute to the incidence or development of new cases. The more important factors 
in this case include age, race, genetic predisposition, and even environmental factors. 
Recent data from 2014 to 2016 has determined the probability of developing prostate 
cancer at different age groups (Siegel et al., 2020). In the United States, these include 
from birth to 49 years of age (0.2% or 1 in 441), 50 to 59 (1.8% or 1 in 57), 60 to 69 
(4.7% or 1 in 21), and greater than or equal to 70 years (8.2% or 1 in 12). Most 
astonishingly, the death rate for prostate cancer has decreased by 52% since 1993 (Siegel 
et al., 2020).  
 From a world perspective, prostate cancer incidence rates are highest in regions of 
high human development like North America and Northern Europe. However, it is 
interesting to note that high mortality rates exist in countries with high proportions of 
African ancestry. These include the Caribbean countries of Barbados and Trinidad 
(Center et al., 2012; Warner et al., 2018).  
1.2 Prostate Specific Antigen and Gleason Score 
 Historically, the emergence of prostate cancer in a patient and its course of 
development were indicated by the measurement of blood PSA levels. The seminal 
research conducted by Stamey et al. in 1987 discovered that the concentration of PSA in 
the blood for patients who did not undergo any prior treatment was indicative of the 
clinical stage of prostate cancer. Moreover, using multivariate regression analysis, it was 
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found that serum PSA concentration was proportional to the volume of the prostate 
cancer tumor. This was an important and vital step for the management of prostate cancer 
as it paved the way to gauge cancer burden on the patient and allowed for a potentially 
directive course for treatment (Stamey et al., 1987). However, there is not a definite 
threshold at which PSA serum concentration represents the presence of cancer. The 
standard protocol was to investigate the presence of cancer in the event that serum PSA 
was >4.0 ng/mL. A PSA concentration of <4.0 ng/mL was considered normal, however 
above this range, a urologist may recommend a patient biopsy (Thompson et al., 2004). 
Recent research has suggested that PSA as a biomarker for cancer is questionable due to 
the fact that high levels may be present in a patient with a clear absence of cancer (Azab, 
Osama, & Rafaat, 2012). Elevated total and free PSA levels could be related to other 
issues unrelated to cancer including prostatitis, urinary tract infections, and even   
masturbation (Azab et al., 2012; Dalton, 1989; Tarhan, Demir, Orcun, & Madenci, 2016).  
 PSA, also known as prostate specific antigen or kallikrein-3, is an enzyme that is a 
part of the kallikrein protein family (Yousef & Diamandis, 2001). The biomolecule 
initially presents as a preproPSA after translation. Subsequent cleavage steps yield the 
active 33 kDa PSA enzyme (Kumar, Mikolajczyk, Goel, Millar, & Saedi, 1997; Lundwall 
& Lilja, 1987). The regulation of the transcription of the PSA gene has been shown to be 
linked to the androgen receptor gene. Therefore, it is recognized as an androgen-regulated 
serine protease. The co-regulation of these transcriptional elements has important 
implications in the understanding of cancer growth and progression (Riegman, Vlietstra, 
van der Korput, Brinkmann, & Trapman, 1991). Typically, PSA presents in the seminal 
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fluid at a concentration of about 0.5 to 2.0 mg/mL (Lovgren, Valtonen-Andre, Marsal, 
Lilja, & Lundwall, 1999). Its function is to help liquify the semen by cleaving the gel-like 
semenogelins in the seminal coagulum. This effectively enables the sperm to swim freely 
(de Lamirande, 2007). Given that PSA is produced from the epithelial cells of the 
prostate gland and functions to cleave other proteins, it may have implications in the 
development and progression of prostate cancer (Catalona, Smith, Ratliff, & Basler, 
1993; Pezaro, Woo, & Davis, 2014). Some research has shown that it has tumor-
promoting qualities by cleaving insulin like growth factor binding protein 3 (IGFBP-3). 
IGFBP-3 binds to insulin-like growth factor-1 (IGF-1) which along with other molecules 
like growth-hormone (GH), help to facilitate somatic growth (P. Cohen, Peehl, Graves, & 
Rosenfeld, 1994). 
 Nevertheless, the importance of PSA can also be represented by the fact that 
higher PSA levels have been shown to correlate to higher tumor grades based on 
histopathologic findings from organ-confined prostate cancer. This suggests the 
association between PSA concentration and Gleason scores (Spencer, Chng, Hudson, 
Boon, & Whelan, 1998). Another groundbreaking work was conducted by Gleason et al.  
to characterize prostate cancer based on a standard grading and prognostic scoring 
system. Cancer scores of lower grades have healthier and normal looking tissue 
compared to higher grades which typically consist of abnormal tissue morphology 





Figure 1: Gleason’s Pattern. The Gleason grading system represents the progression 
from well differentiated to poorly differentiated/anaplastic prostate tissue (Gleason & 
Mellinger, 1974). 
 
1.3 Progression of Prostate Cancer  
Prostate cancer progresses through several phases including organ confined 
cancer growth, spread to local tissue like the seminal vesicles and other organs such as 
the neck of the bladder as well as the rectum, and finally metastasis to regional lymph 
nodes (Simmons, Berglund, & Jones, 2011). Metastasis can also occur in the blood 
spreading to distant areas of the body. The uncontrolled spread of metastatic prostate 
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cancer to the vertebral bone as well as the lungs becomes a very difficult state to manage 
and usually results in rapid death (Simmons et al., 2011).  
 
Figure 2: Anatomy of the Male Reproductive and Urinary Systems. (Adapted from 
PDQ Adult Treatment Editorial Board)  
 
If prostate cancer is detected and diagnosed early, it presents as organ confined 
cancer, or growth directly from the prostate gland. This stage of prostate cancer is 
denoted as T2 using the TNM system (Table 1) for classifying each level of the prostate 
cancer. T2 can then be subdivided into several classes, T2a which is a unilateral lesion 
occupying less than 50% of affected side of the gland, T2b which is a unilateral lesion 
occupying greater than 50% of the affected side of the gland, and T2c which is a bilateral 
lesion (Billis et al., 2019). The urinary system consists of seminal vesicles that 
anatomically lie in close proximity to the prostate gland and therefore may be affected by 
prostate cancer spread. Seminal vesicles store and produce a lot of the fluid that makes up 
semen. The cancer spread to this region is therefore being studied intensively and 
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represents the T3 stage (Panach-Navarrete, Garcia-Morata, Hernandez-Medina, & 
Martinez-Jabaloyas, 2015). The T4 stage for prostate cancer signifies invasion to other 
organs such as the neck of the bladder as well as the rectum wall. Given that these organs 
have their own classes of cancers, a patient that has prostate cancer but presents with 
symptoms related something other than the prostate can be dangerous in the case of an 
incorrect diagnosis (R. J. Cohen, Li, & Shannon, 2016; Tang et al., 2017).  
Prostate cancer can progress to more advanced stages in which there is lymph 
node involvement. Such a spread presents a very serious issue and a very dangerous 
problem for the patient because the lymph node if overwhelmed would compromise its 
immune function. Several areas of study have invested the impact of lymph node 
invasion (LNI) and prognostic factors associated with it in the advent of a patient 
presenting with prostate cancer. Typically, a method used to understand the extent of the 
invasion is the pelvic lymph node dissection (PLND). Patients that had PLND typically 
had more clinically aggressive symptoms and had a lower overall survival (OS) 
compared to patients that did not have PLND (Chen et al., 2019). For high-risk prostate 
cancer, PSA was a clinical factor associated with lymph node invasion. For example, 
median PSA values for extensive lymph node invasion was 23.5 ng/ml compared to 11.4 
ng/ml for limited invasion and 7.3 ng/ml for no invasion (p < 0.0001) (Porcaro et al., 
2018). Due to the invasiveness of such tests, usually as they are performed in conjunction 
with radical prostatectomy, the need for clear and harmless imaging techniques is 
paramount. Studies involving the PET scan uses a radioactive tracer to receive 
comprehensive structural information about the course of a diseased region. Currently, 
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choline and PSMA radiotracers are considered very useful in the context of lymph nodal 
dissection (LND) (Incerti, Mapelli, Gianolli, & Picchio, 2017). Furthermore, the 
minimally invasive MRI-guided pelvic lymph node biopsy has shown promise as a 
method for understanding suspicious nodal spread from prostate cancer (Hague et al., 
2020).  
The final and most lethal stage of prostate cancer is metastasis in the blood to 
distant sites like the bone and lungs. Treatment for metastatic prostate cancer is often 
very minimal due to the diffuse nature of the cancer throughout the body. Understanding 
the use of modern technology and imaging techniques can assist in gauging the cancer 
burden on the body and the specific diseased areas (Umeda et al., 2018). There are 
methods conducted to improve the detection of metastasis including the use of bone 
single photon emission tomography with computed tomography (SPECT/CT). 
Effectively, this method involves the calculation of total bone uptake (TBU), a measure 
of bone metastatic tumor burden (Umeda et al., 2018). Other studies have reviewed the 
use of automated Bone Scan Index (aBSI). It is an imaging tool that has implications in 
understanding survival in metastatic castration resistant prostate cancer. They used a 
multivariable model to understand the association between aBSI and overall survival by 
association with prognostic factors such as serum bone biomarkers (Armstrong et al., 
2018). The first line of therapy post radical prostatectomy when there is a surge in PSA, 
is androgen deprivation therapy. However, the response to this treatment is mostly short 
lived and patients eventually develop resistance to the drug. This leads to aggressive 
tumor growth and metastatic spread of lesions. This is an active area of research and 
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several labs are invested in understanding resistance mechanisms and to identify drugs 
that can improve the response and contain tumor growth (Harris, Mostaghel, Nelson, & 
Montgomery, 2009; Scher & Sawyers, 2005). New techniques like immunotherapy may 
play a huge role in mitigating the effects of metastatic prostate cancer by stimulating the 
immune system for targeted cancer destruction. For example, studies on bone metastatic 
prostate cancer (BM-PCa) has elucidated the significance of neutrophils and their 
infiltration to these regions. Neutrophils are shown to be actively involved in the 
destruction of prostate cancer cells by directly inducing their apoptosis. However, in late 
stage BM-PCa, tumors are able to evade the cytotoxic effects of the neutrophils 
(Costanzo-Garvey et al., 2020). Metastasis can also occur in the lungs (Zang et al., 2015). 
 
Table 1: TNM Staging of Prostate Cancer. (Cosma et al., 2016) 
 
 
1.4 Treatments for Prostate Cancer  
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The treatment options for prostate cancer vary in function and time of 
administration depending on the stage and degree of aggressiveness. The therapies also 
differ in terms of their complex effects on the body in combating cancer growth and 
spread not only at the observable/anatomical scale, but also at the molecular and 
biochemical levels. As such, there are always new studies and research projects aiming to 
develop and discover more appropriate and effective ways of combating cancer (Litwin 
& Tan, 2017). The main therapeutic options for prostate cancer include active 
surveillance, surgery, radiation therapy, hormone therapy, chemotherapy, and 
immunotherapy (Litwin & Tan, 2017). Discussing some of these treatment methods is 
vital in ultimately understanding the biochemical and genetic changes that cause 
alterations in important receptor molecules such as androgen receptor (AR) and 




Figure 3: Treatment Landscape in Prostate Cancer. Diagram representing the different 
treatment options over the course of prostate cancer progression from local disease to 
metastatic (Carreira et al., 2014). 
 
 Several surgical approaches have been useful for managing local prostate cancer. 
These include radical prostatectomy, transurethral resection of the prostate gland, and 
orchiectomy. Radical prostatectomies are regularly performed in the advent of early stage 
prostate cancer because the removal of the entire prostate gland can temporarily reduce 
the effects of cancer and lead to better outcomes (Wilt et al., 2012). In many cases, 
prostate cancer can recur, but the procedure itself has been shown to prolong survival. A 
study showed that those patients receiving a radical prostatectomy had a 5.8% mortality 
rate compared to patients who underwent observation for localized prostate cancer, with 
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an 8.4% morality rate. There was also a significant reduction in all cause morality among 
men with PSA value greater than 10 ng/mL and who received a radical prostatectomy 
(Wilt et al., 2012). Transurethral resection of the prostate is a procedure used to remove a 
section of the gland (Pelletier et al., 2018). The last surgical approach is the least 
favorable because it involves the surgical castration of the patient by removal of the 
testes. Major psychological implications result due to the inability of the patient to 
maintain normal sexual function (Louda et al., 2012). Nevertheless, orchiectomy has 
significant benefits and is even comparable in terms of its positive outcomes on patients 
with cancer compared to other treatment options like radiotherapy. Orchiectomy may 
even have implications in the delay of metastatic prostate cancer (Fellows et al., 1992).    
 If prostate cancer progresses beyond medical intervention involving surgery or 
radiation, hormonal therapies can be an effective option for the patient. There are several 
different classes of hormone treatments including luteinizing hormone therapy (Lee, Kim, 
Choi, Lee, & Cho, 2018), CYP17 inhibitors (Ryan et al., 2013), and even anti-androgen 
drug therapies (Hussain et al., 2018). These classes differ in the biochemical pathways 
they target. These are effective agents for prostate cancer because the tumor cells seem to 
grow and spread rapidly by responding to the androgen production in the body. For 
example, testosterone and dihydrotestosterone (DHT) actually enhance the 
aggressiveness of the prostate cancer tumors (Nishiyama, Ikarashi, Hashimoto, Wako, & 
Takahashi, 2007). Luteinizing hormone agonists can decrease the production of 
androgens like testosterone in the body (Lee et al., 2018). Androgen drug therapies like 
enzalutamide can bind to intracellular receptors in the tumor cells and competitive block 
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androgen binding and subsequent translocation to the nucleus (Tran et al., 2009). 
Hormonal castration is usually a more favorable option for patients compared to surgical 
castration like orchiectomies (Anderson, Abrahamsson, Crawford, Miller, & Tombal, 
2008). Therefore, the more common use of these treatments in practice requires an in-
depth understanding of the pathways that are involved.  
 Studies have illustrated the prognostic significance of testosterone levels in patients 
with metastatic prostate cancer treated with luteinizing hormone-releasing hormone 
therapies (LH-RH). The more widely used LH-RH agonists for the maintenance, not 
treatment of prostate cancer, include leuprolide, triptorelin, and goserelin (Heyns et al., 
2003; Yri, Bjoro, & Fossa, 2006). Common LH-RH agonists were used, and it was found 
that baseline testosterone values were very different from the 6-month testosterone 
readings (mean value at baseline was 440 ng/dL compared to 6-months 40 ng/dL). The 
decrease in testosterone levels indicate that the agonists have worked effectively 
(Perachino, Cavalli, & Bravi, 2010). Castrate levels are defined as testosterone <50 ng/dL 
(Klotz et al., 2015). A study showed that some men treated with leuprolide and goserelin 
reached castrate levels of testosterone after 3 months of being on the therapy (Yri et al., 
2006). The use of leuprolide for instance targets the hypophyseal-gonadal axis. The 
downregulation of GnRH leads to inhibition of production for LH and FSH. As a result, 
testosterone production in the testes is suppressed (Singla, Ghandour, & Raj, 2019). 
LHRH treatments are very effective at reducing the testosterone levels and subsequently 
mitigating the aggressiveness of the tumor cells. However, this form of androgen 
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deprivation therapy (ADT) will ultimately be overcome and inevitably lead to castration 
resistant prostate cancer (CRPC) (Perner et al., 2015).  
 
 
Figure 4: Androgenic Synthesis Signaling Pathways and the Effects of Different 
Drugs. Diagram representing LHRH antagonists disrupting the pathway that normally 
leads to the production of testosterone and DHT (Zhao, Urdaneta, & Anscher, 2016). 
 
 Abiraterone is a CYP17 inhibitor that acts by reducing testosterone levels by 
targeting mainly the adrenal tissue instead of the testes. The adrenal cortex also produces 
androgens such as testosterone that circulates throughout the body (Turcu, Smith, 
Auchus, & Rainey, 2014). Studies were conducted analyzing the effect of abiraterone in 
metastatic prostate cancer patients who did not have prior chemotherapy. Compared to 
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placebo, abiraterone plus prednisone revealed a 57% reducing in the risk of radiographic 
progression or death. Furthermore, patients had a 16.5 month of free survival compared 
to 8.3 months with prednisone alone (Ryan et al., 2013). In patients who had metastatic 
prostate cancer, the overall survival for the abiraterone-prednisone group was 14.8 
months compared to the placebo-prednisone group at 10.9 months (de Bono et al., 2011). 
Abiraterone is an effective agent and this can be shown in prolonged survival of patients 
with metastatic prostate cancer who did not have prior chemotherapy and those that did.  
 The drug enzalutamide is a very common anti-androgen that is used alone or in 
combination with other types of therapies. There are several clinical studies involving 
enzalutamide in combination with other drugs like LHRH agonists, abiraterone, and even 
different forms of chemotherapy (Beer et al., 2014; Iguchi et al., 2019). Enzalutamide is 
used to restrict the aggressiveness of tumors presenting as metastatic castration-resistant 
prostate cancer (Kregel et al., 2016). It targets various nodes within the cancer cell in 
order to maximize its anti-androgen effects (Linder, van der Poel, Bergman, Zwart, & 
Prekovic, 2018). Enzalutamide was the main drug focused in our study, as well. We 
demonstrated the biochemical effects and changes that occur resulting from its 
application. One of the resistant mechanisms in mCRPC that involves enzalutamide is 
glucocorticoid receptor bypass (Arora et al., 2013). We present the need for novel 





Figure 5: AR Signaling Axis and Mechanism of Action of Enzalutamide. This figure 
shows different nodes in the prostate cancer cell that are targeted by enzalutamide drug. 
The effects include binding to the AR protein, preventing translocation to specific genetic 
regions, and inhibiting expression of target genes (Linder et al., 2018). 
 
 As stated above, CRPC can persist if the tumor cells become resistant to ADT. 
Thus, the use of LHRH loses its effectiveness in slowing down progression. The 
requirement for alternative methods targeting tumor cells dependency on androgens is 
imperative. The use of enzalutamide and flutamide are drugs that meet these needs and 
are classified as anti-androgen drugs. In a study conducted using enzalutamide on 
patients who had nonmetastatic, castration resistant prostate cancer, treatment with the 
drug led to a 71% lower risk of metastasis compared to placebo (Hussain et al., 2018). 
These drugs can also be used in the treatment for metastatic castration resistant prostate 
cancer (mCRPC). Groups with metastatic prostate cancer treated with enzalutamide 
(n=872) compared to placebo (n=845) had significant differences for many important 
secondary end points including median time until initiation of cytotoxic chemotherapy, 
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median time until PSA progression, and even median time until first skeletal-related 
event (Beer et al., 2014). Patients who were administered enzalutamide (n=29) or 
flutamide (n=26), showed no significant difference in OS between the groups. Thus, the 
overall effectiveness of the drugs compared to each other is minimal and recognizing 
differences requires more specific analyses. For example, the same study found that the 
PSA-PFS was significantly longer in the enzalutamide group. Many adverse effects can 
occur with the use of these drugs and can include hypertension, liver dysfunction, and 
even diarrhea (Iguchi et al., 2019).  
 Finally, chemotherapy and immunotherapy can be treatment options for patients 
that have advanced metastatic prostate cancer. Common chemotherapeutic agents include 
docetaxel and cabazitaxel. Docetaxel given to patients who had advanced prostate cancer 
every three weeks had a median survival of 18.9 months compared to 17.4 months for the 
group that was given docetaxel weekly (Tannock et al., 2004). Administration of 
cabazitaxel was also found to be useful in targeting CRPC in patients who had prior 
docetaxel chemotherapy (C. J. Pezaro et al., 2014). Immunotherapy is gaining recognition 
as a potential area for targeting advanced prostate cancer. Harnessing the patient’s 
immune system could lead to an alternative way of specifically targeting metastatic 
cancer cells. The only FDA drug for immunotherapy that is used to treat prostate cancer 
is sipuleucel-T. In a randomized, double-blind study, sipuleucel-T showed a 33% 
reduction in the risk of death (Higano et al., 2009). The median survival of patients on 




1.5 Androgen Receptor and Glucocorticoid Receptor 
The importance of understanding the treatment options lies in how they affect the 
molecular biology and the biochemistry of the patient at each stage of the cancer. 
Treatments can be divided based on how they affect the categories of castrate-sensitive 
prostate cancer (CSPC) as well as castrate-resistant prostate cancer (CRPC). CSPC 
specifies the tumor cells’ dependency on the function of the androgen receptor (AR) 
(Hoang, Iczkowski, Kilari, See, & Nevalainen, 2017; Kohli et al., 2020). On the other 
hand, when the tumor cells become resistant to ADT, they progress into what is known as 
CRPC (Perner et al., 2015). Little is known about the biochemical pathways involved in 
the tumor evasion. Research has shown that there still is androgen dependency during 
CRPC, and that it may occur through different means such as AR mutations and 
amplifications (Taplin et al., 1999). However, the dependency for AR can be lost in this 
stage as the patient is taking enzalutamide (Kregel et al., 2016). As a result, there seems 
to be a compensatory mechanism involving glucocorticoid receptor (GR). That is, as AR 
is downregulated, GR seems to be upregulated in CRPC (Arora et al., 2013). As 
mentioned earlier, popular drugs for ADT include leuprolide and goserelin which are 
used during the CSPC stage, when there is androgen sensitivity. Therefore, their effects 
suggest that they are altering the regulation of AR and GR receptors (Sarosdy et al., 
1998). Moreover, drug therapies involving enzalutamide may also facilitate these changes 
because they are common employed during CRPC, an androgen-insensitive stage (Kregel 
et al., 2016).  
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Androgen receptor is a very important biomolecule in prostate cancer. Its function 
ranges from DNA binding-dependent actions to non-DNA binding-dependent actions 
(Eder et al., 2001; Estrada, Espinosa, Muller, & Jaimovich, 2003). When the ligand is 
bound, in this case androgen molecules, the androgen/AR complex dimerizes and 
translocates to specific DNA binding regions (Koivisto, Kolmer, Visakorpi, & 
Kallioniemi, 1998). Attachment of the complex to the androgen response elements 
(AREs) on the DNA allows for specific targeting of genes and modulation of gene 
transcription. The androgen receptor responds to the ARE through its DNA binding 
domain (DBD) (Eder et al., 2001). The androgen receptor seems to have other 
mechanisms of action through non-genomic interactions. Given that the receptor 
molecule is located in the cytosol, convergence of different signals could occur through 
activation of 2nd messenger pathways including ERK, Akt, and MAPK (Kang et al., 2004; 
Kousteni et al., 2001).  
Glucocorticoid receptor (GR) is another important molecule that is involved in 
prostate cancer. Current literature suggests it may play an important part in the 
understanding of how to target cancer spread and aggressiveness (Xie et al., 2015). When 
GR is not bound to a hormone such as cortisol, it is located in the cytosol of cells bound 
to other proteins including heat shock protein 90 and heat shock protein 70. GR can also 
be found complexed to FKBP5 (Pratt, Morishima, Murphy, & Harrell, 2006). When the 
ligand is bound to GR, there is homodimerization of the receptor and translocation to 
different regions of the nucleus. DNA responsive elements that complex with the receptor 
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protein assist in the recognition and transcription of various genes. The function of GR 
closely resembles that of AR (Buckingham, 2006).  
Androgen deprivation therapy effectively slows down the progression of the 
prostate cancer by cutting off the cancer cells’ response and dependency to hormones like 
DHT and testosterone (Heinlein & Chang, 2004). Prostate cancer cells utilize the AR 
protein to bind to androgens like testosterone in order to promote growth and survival 
(Gann, Hennekens, Ma, Longcope, & Stampfer, 1996). ADT has no curative properties 
for prostate cancer. It simply reduces the rate at which the cancer spreads, limits 
aggressiveness, and allows the urologist to effectively manage progression (Harris et al., 
2009).  
Ultimately however, the prostate cancer cells are able to bypass and evade the 
ADT treatment. At this point, the refractory stage of prostate cancer is castration resistant 
prostate cancer (CRPC) (Scher & Sawyers, 2005). Prostate cancer cells seem to become 
dependent on the AR protein again. What has been shown is an upregulation of the 
receptor protein. Treatments like enzalutamide are commonly used to create another 
androgen receptor blockade. Enzalutamide targets several different areas in the cell to 
mechanistically interfere with pathways at multiple points. These include competing with 
the androgens in binding to the AR protein, inhibiting AR nuclear translocation, and 
finally blocking DNA transactivation. Given that enzalutamide targets the AR pathway at 
multiple nodes, it has become a clinically very effective drug (Tran et al., 2009). 
If patients do not respond to enzalutamide, their prostate cancer cells can become 
resistant to the drug. Research has discovered several potential mechanisms of resistance 
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to the drug (Claessens et al., 2014). First, there can be mutations with the AR protein 
receptor. Gain-of-function mutations have led to enhanced activity or upregulation of the 
AR gene. This was the drug was originally trying to counteract (Taplin et al., 1999). 
Next, AR splice variants can occur involving AR-V7. Post-transcriptional modification 
can induce alternatively spliced variants of AR. Isoforms like AR-V7 have been 
implicated in drug resistance to enzalutamide (Guo et al., 2009). Furthermore, GR has 
been shown to be upregulated after resistance to enzalutamide in an attempt by the 
prostate cancer cell to compensate for AR blockade. It has been hypothesized that GR 
takes over the role of AR at this stage, allowing the cells to thrive (Arora et al., 2013). 
Finally, prostate cancer cells can survive by utilizing a method of intratumoral androgen 





Figure 6: Characterizing Gene Expression in Enzalutamide-Resistant Castrate 
Resistant Prostate Cancer. This figure represents expression of AR and GR target genes 
during CRPC when AR protein is bound to either androgens or enzalutamide drug. 
Furthermore, during enzalutamide resistant CRPC, the GR protein takes over the function 
of AR (Arora et al., 2013). 
 
There has been a keen focus on understanding how resistance to enzalutamide 
confers upregulation of the GR protein. Several drugs have been developed to completely 
block GR protein and thus once again interfere with cancer survival (Kach, Conzen, & 
Szmulewitz, 2015). However, the GR protein is located throughout the body in various 
tissue regions. Complete loss of the GR protein could have severely dangerous 
implications. Therefore, research has focused heavily on elucidating the specific effects 
associated with enzalutamide (Oakley & Cidlowski, 2013).  
Upregulation of GR has been characterized as a method of enzalutamide 
resistance in prostate cancer by various means. Resistant cells show an upregulation of 
GR genes, with a simultaneous repression of androgen induced genes (Arora et al., 2013). 
In enzalutamide resistance cells (LREX), knockdown of GR led to a decrease in tumor 
growth. GR expressing resistant tumors showed an uneven restoration of AR target genes 
and even drove AR expression. This suggests that AR and GR had overlapping 
transcriptomes as GR function and transcriptomic action was able to compensate for loss 
of AR. Finally, GR expression was clearly shown to confer enzalutamide resistance 
through analysis of VCaP cells. VCaP cells are enzalutamide-sensitive cells, meaning 
that treatment of the drug can negative impact and reduce their growth. Treatment with 
dexamethasone induced upregulation of GR, conferring resistance of these cell lines. 
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However, when an antagonist to GR was presented, the sensitivity to enzalutamide was 
restored (Arora et al., 2013).  
In other studies, several important characteristics about how enzalutamide 
resistant cells function in relation to GR have been elucidated. Using different genomic 
techniques, it was found that there is a specific GR enhancer that plays a major functional 
role in the resistance in CRPC. It is located on the H3K4me1track within the NR3C1 
locus. Removal of the entire GR enhancer led to a 60% reduction in enzalutamide 
induced GR expression. Thus, excision of the enhancer mitigated GR function. This was 
an important finding because this specific GR enhancer was very unique to the prostate 
cancer tumor cells as opposed to being located in other types of tissues throughout the 
body (Shah et al., 2017).  
Moreover, it was found that EZH2 and AR played very important roles in 
regulating the expression of GR genes (Shah et al., 2017). EZH2 is a gene that plays a 
role in DNA methylation. Specifically, it induces an epigenetic modification at H3K4me3 
(Rosenfeld et al., 2009). H3K4me3 is involved in the reduction of GR expression 
(Caglio, Torlai Triglia, & Pombo, 2017). Under normal circumstances, enzalutamide 
drug promotes the activity of H3K4me3. However, H3K4me3 was not seen in 
enzalutamide resistant prostate cell lines which suggests that when the cells do not 
respond to the drug anymore, the cells do not express H3K4me3. Thus, GR expression is 
very high. Similarly, AR binding at the GR locus reduces GR expression. The research 
also discovered that BET inhibition can be used to re-sensitize the tumor cells to 
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enzalutamide drug by impairing the GR expression. BET proteins help to drive the 
expression of certain tissue specific genes (Shah et al., 2017).  
Given the research and multiple analyses implicating the importance of GR in 
enzalutamide resistance, novel drugs have been created to further attempt to counteract 
cancer growth. GR antagonists such as arylpyrazole, agents targeting downstream AR 
targets, EZH2 inhibitors, and even inhibitors to the PI3K/AKT pathway have showed 
promising results (Arora et al., 2013; Bohrer, Chen, Hallstrom, & Huang, 2010; Carver et 



















 The aim of this project was to characterize GR expression and function and 
downstream targets in prostate cancer cells resistant to enzalutamide. Specifically, we 
wanted to understand whether or not resistance to enzalutamide drug could be reversed in 





















3.1 Overview  
 Multiple enzalutamide resistant prostate cancer cell line clones were 
developed in vitro in order to conduct this research project. In order to model 
enzalutamide resistance, we used prostate cancer LNCaP cell line. This is an androgen 
sensitive CRPC cell line that has intact androgen signaling (Horoszewicz et al., 1983; 
Lim et al., 1993). We looked at cell lines that were androgen sensitive and those that 
were androgen resistant for the purpose of characterizing GR and the downstream targets. 
Cell culture involved preparation of the specific colonies of interest. Western blots were 
used to analyze and characterize specific protein content in the cells. qPCR was used to 
amplify specific regions of DNA. 





Figure 7: Development of Enzalutamide Cell Lines. LNCaP ATCC cells were grown in 
vitro. Treatment of enzalutamide to these AR sensitive cells occurred over the course of 6 
months and allowed them to develop in response to the drug. Clonal selection was followed 
in order to begin the process of deeper investigative work and to characterize cellular 
response to enzalutamide.  
 
 The prostate cancer parental cell lines that we used for this study included LNCaP 
that were obtained from ATCC. The LNCaP cells are androgen-sensitive prostate cancer 
cell lines that were obtained from a left supraclavicular lymph node metastasis 
(Horoszewicz et al., 1983; Lim et al., 1993). LNCaP cells were cultured for several 
weeks in vitro. The cells were cultured with enzalutamide drug (10uM/ml of media) for 
about 6 months until there was clonal growth. Clonal selection of colonies occurred after 
treatment with enzalutamide drug. We expanded the clones that were resistant to 
enzalutamide treatment and characterized the clones. This was ongoing research in the 
laboratory.  
3.3 Drugs/Chemicals 
 Different drugs were administered to these prostate cancer cell lines over the 
course of colony development. These drugs included enzalutamide as well as several GR 
inhibitors. Drugs were given in various doses and combinations for the same colonies. 
Preparation of enzalutamide involved dissolving and aliquoting it in media. Media 
consisted of 500 mL of RPMI, 10% FBS, and 5 mL of antimicrobial solution. GR 
inhibitors are associated with a company that does not want to disclose any information 





3.4 Western Blot  
 Protein lysates for the western blot were prepared based on the cell lines we were 
interested in analyzing. The lysate solution used consisted of these chemicals. Centrifuging 
the lysates to separate protein supernatant from the cellular debris was performed. Lysate 
protein samples were divided up and labeled based on the various drug treatments and 
combinations used when preparing the colonies in vitro.  
 Protein estimation or quantification was then used to determine the total protein 
concentration for the sample lysates. Proper estimation was necessary to accurately 
determine the necessary amount of protein to load for each lane in the gel. In this case, a 
spectrophotometric technique measured the protein concentration sample based on 
specific absorbance patterns. Subsequent mathematical analysis involved normalizing the 
sample values, calculating the amount of 4x dye used, and determining the amount of 
lysis buffer to combine in each Eppendorf tube with their respective protein lysates. 
Protein estimation values were also compared to standard sample measurements as a 
benchmark for proper loading of the solutions.  
 In preparation for running the electrophoresis, we make 10% gels. The separating 
solutions consisted of dionized H20, 30% acrylamide mix, Tris-Cl (1.5 M, pH 8.8), 10% 
SDS, 10% ammonium persulfate, and TEMED (Bio-Rad Laboratories, Inc.). The 
stacking solution for the gel consisted of the same chemicals although Tris-Cl (1.0 M, pH 
6.8) instead of Tris-Cl (1.5 M, pH 8.8) was used. The running buffer consisted of 25mM 
Tris-base, 192mM glycine, and 0.1% SDS (Bio-Rad Laboratories, Inc.). The gel was run 
at 133 volts for an hour.  
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 Next, the transfer of the protein samples from the gels to the membrane was 
performed. The transfer buffer consisted of 25mM Tris-base, 192mM glycine, and 
nitrocellulose or 10% methanol. The transfer apparatus was operated at 73 volts for about 
an hour and a half.  
 Staining of the membrane involved shaking in ponceau solution to gauge the 
consistency of the bands as well as the band strength. The membranes were then placed 
in a 3% blocking solution consisting of TBST and milk powder. The blocking of the 
membrane took an hour. The TBST solution was also used for washing the membranes 
after blocking solution and probing for primary and secondary antibodies. TBST consists 
of Tris-Cl (pH 7.5), NaCl, deionized H20, and Tween (Bio-Rad Laboratories, Inc.). 
Thorough washes were primarily 3 times, 10 minutes each.  
 Primary antibodies and secondary antibodies were used for probing specific 
proteins of interest that were on the membrane. Antibodies were added to the 3% 
blocking solution at various dilutions depending on the strength and sensitivity of the 
antibody. Antibody targets were for AR and GR often in 1:2000 dilutions. The secondary 
antibody used for these protein targets was anti-rabbit. Primary antibodies were placed on 
the shaker for 1 hour and secondary antibodies were placed on the shaker for 1.5 hours at 
room temperature. 
3.5 qPCR 
 For qPCR we used the Ssoadvanced universal SYBR green supermix kit (Bio-
Rad Laboratories, Inc.). The components were initially thawed at room temperature prior 
to starting the experiment. We used a volume of 5 ul of the Ssoadvanced universal SYBR 
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green supermix at a 2x concentration per 10 ul reaction in order to obtain a final 1x 
concentration. Furthermore, the preparation involved 1 ul of the cDNA, 3 ul of water, and 
1 ul of forward and reverse primers. The final volume of the reaction mix was 10 ul. All 
of the contents were thoroughly mixed to ensure homogeneity and were aliquoted into the 
PCR tubes (Bio-Rad Laboratories, Inc.).  
 The thermal cycling protocol was then performed on the CFX384 Touch real-time 
PCR system. Polymerase activation and amplification occurred at 95 degrees Celsius for 
30 seconds and at 40 cycles. It was also done at 95 degrees Celsius for 15 seconds and at 
60 cycles.  
3.6 Statistical Analyses 
 For this experiment, we used the GraphPad statistics program to analyze the data 
gathered from the qPCR experiment. The qPCR experiment provided data on mRNA 
expression for different AR and GR targets. We ran multiple unpaired t-tests using the 
GraphPad software in order to look for significant differences between the mean values 
for the various AR and GR targets and their respective treatments (untreated, GR 
inhibitor 1, GR inhibitor 2). Significant p-values were represented at different levels 










 The microscopic images in Figure 8 showcase the effects of treatment with 
enzalutamide drug to LNCaP cell cultures. LNCaP cells that were treated with the drug had 
clear morphological changes, that were expected. Clumping of the cells and colony 
formation indicated in Figure 8b and 8c represent the characteristic cellular changes that 
occur in the process of developing resistance to the drug. The opposite can be seen in Figure 
8a. LNCaP cells that were not treated with enzalutamide, but rather media alone, showed 
normal growth patterns. 
The western blot in Figure 9 illustrated the bands for actin that was used as an 
internal control. This indicates that the protein levels were correctly normalized across 
the different LNCaP cell lines.  
 The western blot diagram also illustrates stronger GR band signals for LnE-1,2,4 
and 6 compared to LnE-8,A, and B. This suggests that enzalutamide resistance induced 
an upregulation of GR signaling in those selected clones. Alternatively, AR seems to be 
slightly downregulated in LnE-1,2,4, and 6 due to weaker band signals. Taken together, 
this information suggests that AR and GR may be linked and that a compensatory 
mechanism upregulates GR as AR is downregulated.  
 When analyzing LNCaP cells with no prior enzalutamide treatment, there was a band 
for the AR protein and an absence of a band for the GR protein. This result was to be 
expected because these cells are AR-positive cells that are not resistant to enzalutamide 
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and therefore are dependent on AR signaling. Furthermore, without prior treatment of the 
drug, we should not expect for there to be a high presence of GR. 
 Figure 10 indicates the AR targets that we screened in terms of relative mRNA 
expression. Relative mRNA expression levels of the AR targets were compared based on 
cells treated with either GR inhibitor 1 or 2, or untreated cells. Some of these targets were 
inhibited by GR inhibitors 1 and 2 compared to the untreated samples. These included 
AR, PSMA, PSA, and PAP. However, there were increases in relative mRNA expression 
for TRPM8, NKX3.1, and KLK2 after the GR inhibitors 1 and 2 compared to the 
untreated samples. Notably, there were significant decreases in mRNA expression for AR 
between untreated samples and those treated with GR inhibitor 1, t(4)=12.33, p=0.0002 
as well as between untreated and treated with GR inhibitor 2, t(4)=12.99, p=0.0002. 
There were significant differences in mRNA expression for PSMA between untreated 
and treated with GR inhibitor 1 and 2, t(4)=25.38, p=0.0001 and, t(4)=31.505, p=0.0001, 
respectively. There were also significant differences in mRNA expression for PSA 
between untreated and those treated with GR inhibitor 1 and 2, t(4)=5.47, p=0.0054 and, 
t(4)=13.47, p=0.0002, respectively. Finally, there were significant decreases in mRNA 
expression for PAP between untreated and GR inhibitors 1 and 2, t(4)=4.61, p=0.0099 
and , t(4)=4.61, p=0.0099, respectively. There were no significant differences in terms of 
mRNA expression between treatments for TRPM8, NKX3.1, and KLK2. Collectively, 
this data indicates that the treated cells had blocked AR signaling due to lower expression 




a. LNCaP-ATCC            b. LnE-Clone #2                        c. LnE-Clone A 
 
Figure 8: Microscope images of model cell lines. Microscopic images illustrating a. 
LNCaP ATCC cells with no treatment of enzalutamide drug compared to b-c. which 
consisted of different clone groups that were treated with enzalutamide drug. LNCaP-
ATCC did not form major colonies or clusters which indicates that their growth and 
development persisted on media alone. LnE-Clone #2 and LnE-Clone A clearly indicates 
the development of colony formation. The subsistence of colonies during the course of 




Figure 9: Identifying molecular trends in model cell lines. Western blot represents the 
LNCaP and enzalutamide resistant LnE clonal cell lines 1,2,4,6,8,A, and B. Actin served 
as an internal control. The presence or absence of AR and GR proteins are indicated by 






Figure 10: GR and AR Targets. This graph depicts various AR targets and their relative 
mRNA expression for untreated samples and those that were treated with two different GR 
inhibitors. There were substantial differences in mRNA expression between untreated 
samples versus GR inhibitors 1 and 2 for mRNA expression of PSA and PAP which are 
the key AR target genes. Significant p-values depicted in the graph were represented 



















 Current literature has suggested that during the metastatic stage of prostate cancer 
after the tumor cells have bypassed ADT, the AR protein may be upregulated again, and 
a newfound dependency of this signaling molecule occurs (Taplin et al., 1999). We have 
shown that this trend occurs by analyzing the western blot in Figure 9. In the LNCaP 
cells, the prostate cancer metastatic cells that are androgen-sensitive, the AR molecule 
has a strong signal and band strength (Lim et al., 1993). The GR molecule is notably 
absent as should be expected in this case because, in these cells, there is no AR blockade, 
and there is no need to bypass downregulation of AR with a compensatory mechanism 
(Lim et al., 1993).  
 However, while analyzing the other cell lines that were treated with the drug and 
eventually developed resistance to enzalutamide, there is a slightly different trend. In this 
case, some of the cell lines exhibit weak AR signals with a compensatory upregulation of 
the GR band signals. In this case, we have been able to mimic the enzalutamide 
resistance that occurs during the standard treatment of mCRPC.  
 Figure 10 illustrates the effect of GR inhibitors 1 and 2 on canonical AR targets. 
With the application of these inhibitors, AR, PSMA, PSA, and PAP have lower levels of 
mRNA expression compared to their untreated counterparts. The significance of this is 
that the cell’s expressivity of these genetic elements is curbed in the advent that this 
potent inhibitor is applied. Moreover, this graph indicates that targeting GR is important 
as it seems to be involved in the expression of commonly known AR genes and target 
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elements. Astonishingly, there is a significant drop in expression levels of PSA and PAP 
from untreated samples. The presence and aggressiveness of prostate cancer cells have 
been measured using PSA levels and PAP levels. Higher levels, although not always 
accurate, indicate the presence of cancer (Catalona et al., 1994; Lin et al., 1998). The 
levels illustrated in figure 10 seem to suggest that the GR inhibitor reduces tumor burden. 
This is vitally important because this GR inhibitor could be used in combination with 
enzalutamide and create a more potent AR signaling blockade.  
 Similarly, there are reductions in the mRNA expression of AR and PSMA. AR has 
notoriously been implicated in tumor aggression and resistance. AR proteins respond to 
the androgen levels in the body by binding to DHT and testosterone. AR translocation to 
the nucleus enhances the growth and survival of the tumor cells (Koivisto et al., 1998). 
Reducing the targeted expression of AR suggests the importance of this drug as a targeted 
treatment. PSMA has also been shown to be associated with prostate cancer concerning 
its activation of the PI3K pathway (Caromile & Shapiro, 2017). Reductions in the 
expression of this protein molecule represent another way of targeting and reducing 
cancer burden. Specifically, GR inhibitor 2 rather than 1 induces a more significant 
reduction in AR, PSMA, PSA, and PAP, suggesting that it is more potent and effective 
compared to the other drug.  
 Figure 10 also indicates that GR inhibitors 1 and 2 cause an increase in mRNA 
expression of TRPM8, NKX3.1, and KLK2 compared to untreated conditions. TRPM8 is 
typically associated and elevated with androgen-dependent prostate cancer cells or 
androgen-sensitive cells like LNCaPs. Under normal conditions and with healthy 
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prostatic cells, its level is not largely expressed. TRPM8 has been implicated to have a 
protective role and seems to modulate the regulation of calcium ions during cancer 
invasiveness (Grolez & Gkika, 2016; Zhang & Barritt, 2006). Minor expression of the 
TRPM8 molecule in figure 10 could indicate that the GR inhibitors play a minor role in 
returning the cell to an androgen-dependent – like state.  
      NKX3.1 is a prostatic tumor suppressor gene that is almost completely lost in the 
majority of metastatic prostate cancers (Zhang & Barritt, 2006). However, here we see a 
significant expression of the gene compared to baseline with the administration of GR 
inhibitors. Effectively, the inhibitors are restoring the tumor suppressor activity that was 
initially lost. Furthermore, NKX3.1 is a shared AR and GR target. This suggests that GR 
is indeed functional.  
      The toxic effect of KLK2, being a genetic element that has cellular properties 
conducive to tumorigenesis, means that higher expression of this AR target is not 
beneficial in mitigating tumor burden (Shang et al., 2014). This is exactly what is seen 
when the GR inhibitors are used as a treatment. Although there are no clear functions of 
KLK2, it is typically associated with lower apoptosis and higher cell proliferation (Shang 
et al., 2014).  
 The protein patterns seen in the western blot, as well as the mRNA expression 
levels seen in the qPCR data, have characterized various target elements and pathways 
involved in AR signaling for enzalutamide resistant cells. The knockdown of the AR 
protein and the newfound dependency of GR protein in maintaining AR signaling suggest 
complicated overlapping pathways and the potential need for new combination therapies. 
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This research elucidates some of the intricate signaling pathways that involve AR target 

























 During the metastatic setting of prostate cancer, when patients are given the first 
line of therapy, which is ADT, there is an improvement in the disease. Still, life 
expectancy only improves for a couple of months (Harris et al., 2009). What happens is 
that patients eventually develop resistance to this drug and stop responding to the 
medication. Then the tumor cells become even more aggressive. So, at that point, there is 
an increased need to find other therapies or combination therapies that would improve the 
sensitivity to enzalutamide (Scher & Sawyers, 2005). Active studies are being done to 
understand these problems, and researchers have used different model systems to 
understand what is going on (Scher & Sawyers, 2005). For example, this can be seen in 
the characterization of the biology or the signaling, and if there are drugs that can be 
proposed as combination therapies (Litwin & Tan, 2017). In our lab, we wanted to 
understand how enzalutamide resistance can be reversed or if we could restore the 
sensitivity to the drug. To do that, we had to develop cell lines and look at different 
signaling markers to understand what is targetable and to see the signaling that is 
functional in these cells. Existing literature suggests that there is an increase in GR in 
these cell lines (Arora et al., 2013). So, this means that GR is an excellent mechanism to 
bypass resistance and targeting that could be very relevant. In characterizing GR and the 
downstream targets, we found that both GR and GR signaling is present in these cell 
lines. Furthermore, using qPCR to measure mRNA expression of different AR and GR 
targets suggests that novel GR inhibitors 1 and 2 may prove to be useful in combating 
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cancer growth. Targeting GR could be a good option either alone or in combination with 
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